Literature DB >> 34116789

American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus.

George Grunberger1, Jennifer Sherr2, Myriam Allende3, Thomas Blevins4, Bruce Bode5, Yehuda Handelsman6, Richard Hellman7, Rosemarie Lajara8, Victor Lawrence Roberts9, David Rodbard10, Carla Stec11, Jeff Unger12.   

Abstract

OBJECTIVE: To provide evidence-based recommendations regarding the use of advanced technology in the management of persons with diabetes mellitus to clinicians, diabetes-care teams, health care professionals, and other stakeholders.
METHODS: The American Association of Clinical Endocrinology (AACE) conducted literature searches for relevant articles published from 2012 to 2021. A task force of medical experts developed evidence-based guideline recommendations based on a review of clinical evidence, expertise, and informal consensus, according to established AACE protocol for guideline development. MAIN OUTCOME MEASURES: Primary outcomes of interest included hemoglobin A1C, rates and severity of hypoglycemia, time in range, time above range, and time below range.
RESULTS: This guideline includes 37 evidence-based clinical practice recommendations for advanced diabetes technology and contains 357 citations that inform the evidence base. RECOMMENDATIONS: Evidence-based recommendations were developed regarding the efficacy and safety of devices for the management of persons with diabetes mellitus, metrics used to aide with the assessment of advanced diabetes technology, and standards for the implementation of this technology.
CONCLUSIONS: Advanced diabetes technology can assist persons with diabetes to safely and effectively achieve glycemic targets, improve quality of life, add greater convenience, potentially reduce burden of care, and offer a personalized approach to self-management. Furthermore, diabetes technology can improve the efficiency and effectiveness of clinical decision-making. Successful integration of these technologies into care requires knowledge about the functionality of devices in this rapidly changing field. This information will allow health care professionals to provide necessary education and training to persons accessing these treatments and have the required expertise to interpret data and make appropriate treatment adjustments.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  automated insulin dosing; continuous glucose monitoring; continuous subcutaneous insulin infusion; diabetes; diabetes technology; glucose sensors; hybrid closed loop; insulin pumps; low-glucose suspend; predictive low-glucose suspend; sensor-augmented pump

Year:  2021        PMID: 34116789     DOI: 10.1016/j.eprac.2021.04.008

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  13 in total

1.  More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data.

Authors:  Richard M Bergenstal; Gregg D Simonson; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2021-10-28

Review 2.  Diabetes: the role of continuous glucose monitoring.

Authors:  Julianna Rivich Kluemper; Alexandria Smith; Brooke Wobeter
Journal:  Drugs Context       Date:  2022-06-14

3.  Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.

Authors:  John J Isitt; Stéphane Roze; Helen Sharland; Greg Cogswell; Hamza Alshannaq; Gregory J Norman; Peter M Lynch
Journal:  Diabetes Ther       Date:  2022-10-19       Impact factor: 3.595

4.  Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.

Authors:  Ileana Mardare; Stephen M Campbell; Johanna C Meyer; Israel Abebrese Sefah; Amos Massele; Brian Godman
Journal:  Front Pharmacol       Date:  2022-01-14       Impact factor: 5.810

Review 5.  Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus.

Authors:  Jin Yu; Seung-Hwan Lee; Mee Kyoung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-02-28

6.  'Striving for freedom or remaining with what is well-known': a focus-group study of self-management among people with type 1 diabetes who have suboptimal glycaemic control despite continuous subcutaneous insulin infusion.

Authors:  Margareta Persson; Janeth Leksell; Åsa Ernersson; Ulf Rosenqvist; Åsa Hörnsten
Journal:  BMJ Open       Date:  2022-04-01       Impact factor: 2.692

Review 7.  Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices.

Authors:  Rodolfo J Galindo; Ketan Dhatariya; Fernando Gomez-Peralta; Guillermo E Umpierrez
Journal:  Curr Diab Rep       Date:  2022-05-04       Impact factor: 5.430

Review 8.  Social Care Recommendations in National Diabetes Treatment Guidelines.

Authors:  Benjamin Aceves; Rose Gunn; Maura Pisciotta; Na'amah Razon; Erika Cottrell; Danielle Hessler; Rachel Gold; Laura M Gottlieb
Journal:  Curr Diab Rep       Date:  2022-08-30       Impact factor: 5.430

9.  Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients.

Authors:  Yaxin Wang; Jingyi Lu; Yun Shen; Jiaying Ni; Lei Zhang; Wei Lu; Wei Zhu; Yuqian Bao; Jian Zhou
Journal:  J Diabetes Investig       Date:  2022-05-06       Impact factor: 3.681

10.  Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

Authors:  Anders L Carlson; Jennifer L Sherr; Dorothy I Shulman; Satish K Garg; Rodica Pop-Busui; Bruce W Bode; David R Lilenquist; Ron L Brazg; Kevin B Kaiserman; Mark S Kipnes; James R Thrasher; John H Chip Reed; Robert H Slover; Athena Philis-Tsimikas; Mark Christiansen; Benyamin Grosman; Anirban Roy; Melissa Vella; Richard A M Jonkers; Xiaoxiao Chen; John Shin; Toni L Cordero; Scott W Lee; Andrew S Rhinehart; Robert A Vigersky
Journal:  Diabetes Technol Ther       Date:  2021-11-16       Impact factor: 6.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.